[1] He Y.,Harrington B. S.,Hooper J. D. .2016 .New crossroads for potential therapeutic intervention in cancer - intersections between CDCP1, EGFR family members and downstream signaling pathways. Oncoscience, 5(1) : .
[2] Wang R.,Wang X.,Wu J. Q.,Ni B.,Wen L. B.,Huang L.,Liao Y.,Tong G. Z.,Ding C.,Mao X. .2016 .Efficient porcine reproductive and respiratory syndrome virus entry in MARC-145 cells requires EGFR-PI3K-AKT-LIMK1-COFILIN signaling pathway. Virus Res., 225(23) : .
[3] Yewale C.,Baradia D.,Patil S.,Misra A. .2013 .Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. , 8690(34) : .
[4] Cho A.,Hur J.,Moon Y. W.,Hong S. R.,Suh Y. J.,Kim Y. J.,Im D. J.,Hong Y. J.,Lee H. J.,Kim Y. J.,Shim H. S.,Lee J. S.,Kim J. H.,Choi B. W. .2016 .Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in nonsmall cell lung cancer. BMC Cancer, 16(1471) : .
[5] Wang K.,Li D.,Sun L. .2016 .High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancer, Onco Targets Ther. , 9(377) : .
[6] Imamura F.,Uchida J.,Kukita Y.,Kumagai T.,Nishino K.,Inoue T.,Kimura M.,Oba S.,Kato K. .2016 .Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. Lung Cancer, 94(68) : .
[7] Holdman X. B.,Welte T.,Rajapakshe K.,Pond A.,Coarfa C.,Mo Q.,Huang S.,Hilsenbeck S. G.,Edwards D. P.,Zhang X.,Rosen J. M. .2015 .Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer. Breast Cancer Res., 17(1465) : .
[8] Oda K.,Matsuoka Y.,Funahashi A.,Kitano H. .2005 .A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol, 1(1) : .
[9] Minkovsky N.,Berezov A. .2008 .a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr. Opin. Investig. Drugs., 1336(12) : .
[10] M. Burotto V. L.,Chiou J. M.,Lee E. C.,Kohn E. C. .2014 .The MAPK pathway across different malignancies: a new perspective. Cancer, 3446(22) : .
[11] Yang G. F.,Huang X. Q. .2006 .Development of quantitative structure-activity relationships and its application in rational drug design. Curr, 4601(35) : .
[12] Cherkasov A.,Muratov E. N.,Fourches D.,Varnek A.,Baskin I. I.,Cronin M.,Dearden J.,Gramatica P.,Martin Y. C.,Todeschini R.,Consonni V.,Kuz V. E.,Benigni R.,Yang C.,Rathman J.,Terfloth L.,Gasteiger J.,Richard A. .2014 .QSAR modeling: where have you been? where are you going to?. J. Med, 4977(12) : .
[13] J. Shim A. D.,Mackerell A. D. .2011 .Computational ligandbased rational design: role of conformational sampling and force fields in model development. Medchemcomm, 356(5) : .
[14] J. Ghasemi M.,Salahinejad M.,Rofouei M. .2011 .Review of the quantitative structure-activity relationship modelling methods on estimation of formation constants of macrocyclic compounds with different guest molecules. Supramol. Chem, 614(9) : .
[15] Hopfinger A.,Wang S.,Tokarski J. S.,Jin B.,Albuquerque M.,Madhav P. J.,Duraiswami C. .1997 .Construction of 3D-QSAR models using the 4DQSAR analysis formalism. J. Am. Chem. Soc., 10509(43) : .
[16] Martins J. P.,Barbosa E. G.,Pasqualoto K. F.,M. K. F. .2009 .M. Ferreira, LQTA-QSAR: a new 4D-QSAR methodology. J. Chem, 1428(6) : .
[17] Barbosa E. G.,M. M. Ferreira E. G. .2012 .Digital filters for molecular interaction field descriptors. Mol. Inform, 75(1) : .
[18] Teofilo R. F.,Martins J. P. A.,M. M. Ferreira J. P. A. .2009 .Sorting variables by using informative vectors as a strategy for feature selection in multivariate regression. J. Chemom., 32(1) : .
[19] Hemmateenejad B.,Miri R.,Akhond M.,M. M. .2002 .Shamsipur, QSAR study of the calcium channel antagonist activity of some recently synthesized dihydropyridine derivatives. an application of genetic algorithm for variable selection in MLR and PLS methods, Chemometrics Intellig. , 91(1) : .
[20] A. J. Bridges H. R.,Zhou D. R.,Cody G. W.,Rewcastle A.,McMichael H. D.,Showalter D. W.,Fry A. J.,Kraker W. A.,Denny W. A. .1996 .Tyrosine kinase inhibitors. 8. an unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)- 6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med, 267(1) : .
[21] Li S.,Guo C.,Zhao H.,Tang Y.,Lan M. .2012 .Synthesis and biological evaluation of 4-[3-chloro-4-(3- fluorobenzyloxy)anilino]-6-(3-substitutedphenoxy)pyrimidines as dual EGFR/ErbB-2 kinase inhibitors. Bioorg. Med, 877(2) : .
[22] Suzuki N.,Shiota T.,Watanabe F.,Haga N.,Murashi T.,Ohara T.,Matsuo K.,Oomori N.,Yari H.,Dohi K.,Inoue M.,Iguchi M.,Sentou J. .2011 .Synthesis and evaluation of novel pyrimidinebased dual EGFR/Her-2 inhibitors, Bioorg. , 1601(6) : .
[23] Waterson A. G.,Petrov K. G.,Hornberger K. R.,Hubbard R. D.,Sammond D. M.,Smith S. C.,Dickson H. D.,Caferro T. R.,Hinkle K. W.,Stevens K. L.,Dickerson S. H.,Rusnak D. W.,Spehar G. M.,Wood E. R.,Griffin R. J.,Uehling D. E. .2009 .Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors. Bioorg. Med, 1332(5) : .
[24] Peräkylä M. .2001 .New energy terms for reduced protein models implemented in an offlattice force field. J. Comput. Chem, 1229(12) : .
[25] Pettersen E. F.,Goddard T. D.,Huang C. C.,Couch G. S.,Greenblatt D. M.,Meng E. C. .2004 .a visualization system for exploratory research and analysis. J. Comput. Chem, 1605(13) : .
[26] D. Van Der Spoel B.,Hess B. . .. , : .
[27] J.Chem.Soc.Pak. ,Mark A. E.,Berendsen H. J. .2005 .. J. Comput. Chem, 1701(16) : .
[28] Darden T. .1993 .Particle mesh ewald: an N⋅log (N) method for ewald sums in large systems. J. Chem. Phys., 10089(12) : .
[29] H. J. Berendsen J. V.,Postma W. F. van Gunsteren,A. DiNola J. R.,Haak J. R. .1984 .Molecular dynamics with coupling to an external bath. J. Chem. Phys., 3684(8) : .
[30] Patil R.,Sawant S. .2015 .Molecular dynamics guided receptor independent 4D QSAR studies of substituted coumarins as anticancer agents. Curr. Comput. Aided Drug Des., 39(1) : .
[31] Wang Y.,Chu D.,Yan H. .2019 .4D-QSAR and MIA-QSAR study on the bruton's tyrosine kinase (Btk) inhibitors. Mol. Graph, 92(357) : .
[32] J. de Campos .2014 .Modeling structure-activity relationships of prodiginines with antimalarial activity using GA/MLR. Mol. Graph, 54(19) : .
[33] E. B. de Melo J. P. A.,Martins E. H.,Miranda E. H.,M. M. C. Ferreira E. H. .2016 .A best comprehension about the toxicity of phenylsulfonyl carboxylates in vibrio fischeri using quantitative structure activity/property relationship methods. J. Hazard. Mater., 304(233) : .
[34] Gramatica P.,Chirico N.,Papa E.,Cassani S.,QSARINS: S. .2013 .a new software for the development, analysis, and validation of QSAR MLR models. J. Comput. Chem, 2121(24) : .
[35] R. B. Patil E. G.,Barbosa J. N.,Sangshetti S. D.,Sawant V. P.,Zambre V. P.,Golbraikh A.,Tropsha J.,Mol J. .2002 .a new 3D-QSAR methodology applied to a set of DGAT1 inhibitors. Computat. Biol. Chem, 269(4) : .
[36] Golbraikh A.,Tropsha A. .2002 .Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. Mol. Divers, 231(4) : .
[37] Balupuri A.,Balasubramanian P. K.,Cho S. J.,Chem S. J. .2020 .dynamics simulation and free energy calculation studies of some pyrimidine derivatives as novel JAK3 inhibitors, Arab. , 1052(1) : .
[38] Kiralj R.,Ferreira M. .2009 .Basic validation procedures for regression models in QSAR and QSPR studies: theory and application. J. Braz. Chem. Soc., 770(4) : .